SEC filing record
Primary Source · SEC.gov

Pathology Watch Inc.

2023 vintageRule 506(c)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Raised

$22M

Investors

88

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Pathology Watch Inc. is a Delaware corporation that filed a Form D with the SEC on March 7, 2023 in the Other Technology industry group. The offering claims Rule 506(c) and covers equity. Pathology Watch Inc. reported $22,337,584 sold from 88 investors of a $25,000,000 total offering as of the Form D filed March 7, 2023. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names CEROS FINANCIAL SERVICES, INC. (CRD 37869), associated with None as the recipient of sales compensation soliciting in all states. The issuer's address of record is 497 West 4800 South, Suite 201, Murray, UT 84123.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001775372
Entity NamePathology Watch Inc.
ExemptionRule 506(c)
What the exemption meansRule 506(c) of Regulation D: the issuer may advertise the offering publicly, but every purchaser must be a verified accredited investor.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address497 West 4800 South, Suite 201, Murray, UT 84123
Phone(877) 463-5434
Industry / Fund TypeOther Technology
Securities TypeEquity
First Sale DateDecember 29, 2021
Filing DateMarch 7, 2023
Accession Number0001775372-23-000002
Total Offering Amount$25,000,000
Total Amount Sold$22,337,584
Amount Remaining$2,662,416
Total Investors88
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)UT
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

0

none on file

Critical / warning

0 / 0

0 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

3

lapsed

Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2023-03-07: 3 related persons added and 2 removed against the filing of 2020-05-13; 6 now listed. The names are in the Terminal feed.

Daniel Lambert

Executive Officer, Director · MURRAY, UT

Arjun Desai

Director · MURRAY, UT

Michael Torno

Executive Officer, Director · MURRAY, UT

Austin Walters

Director · MURRAY, UT

Rick Stratford

Director · MURRAY, UT

Scott Mattivi

Executive Officer · MURRAY, UT

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

CEROS FINANCIAL SERVICES, INC.CRD 37869 on BrokerCheck

Associated broker-dealer: None · ROCKVILLE, MD · Soliciting in all states

Questions About Pathology Watch Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Pathology Watch Inc.?

Pathology Watch Inc. is a Delaware corporation that filed a Form D with the SEC on March 7, 2023 in the Other Technology industry group. The filing claims Rule 506(c) for an offering of equity.

Is Pathology Watch Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Pathology Watch Inc. filed a Form D with the SEC on March 7, 2023 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $22,337,584 sold to 88 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Pathology Watch Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Pathology Watch Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Pathology Watch Inc. raised?

Pathology Watch Inc. reported $22,337,584 sold from 88 investors of a $25,000,000 total offering as of the Form D filed March 7, 2023.

Who can invest in Pathology Watch Inc.?

The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Pathology Watch Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Pathology Watch Inc. and how are they paid?

The Form D names CEROS FINANCIAL SERVICES, INC. (CRD 37869), associated with None as the recipient of sales compensation soliciting in all states.

Who is behind Pathology Watch Inc.?

The Form D lists 6 related persons: Daniel Lambert, executive officer, director; Arjun Desai, director; Michael Torno, executive officer, director; Austin Walters, director; Rick Stratford, director; Scott Mattivi, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Pathology Watch Inc. located?

The issuer's address on its SEC filings is 497 West 4800 South, Suite 201, Murray, UT 84123. Its phone number of record is 877-463-5434. It is organized under the laws of Delaware.

How long is the Pathology Watch Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Pathology Watch Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.